Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
IGM Biosciences, Inc.
Taiho Pharmaceutical Co., Ltd.
TG Therapeutics, Inc.
Mayo Clinic
Valerio Therapeutics